AML with CBFB-MYH11 rearrangement demonstrate RAS pathway alterations in 92% of all cases including a high frequency of NF1 deletions

作者:Haferlach C*; Dicker F; Kohlmann A; Schindela S; Weiss T; Kern W; Schnittger S; Haferlach T
来源:Leukemia, 2010, 24(5): 1065-1069.
DOI:10.1038/leu.2010.22